| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CDKN2A;CDKN2;MTS1;Cyclin-dependent kinase inhibitor 2A;isoforms 1/2/3;Cyclin-dependent kinase 4 inhibitor A;CDK4I;Multiple tumor suppressor 1;MTS-1;p16-INK4a;p16-INK4;p16INK4A;p16 |
| Antigen | |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Conjugate | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human p16-INK4a around the phosphorylation site of Ser152. AA range:107-156 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
U-Blot® p16-INK4a (Phospho Ser152) Rabbit Polyclonal Antibody is a rabbit polyclonal antibody from UcallM Biosciences Inc, raised against p16. Recognizes Phospho. It has been validated for Western Blot, Immunohistochemistry, Immunofluorescence, ELISA and reacts with Human.
Validated Applications
| Target | p16 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human |
| Applications | Western Blot, Immunohistochemistry, Immunofluorescence, ELISA |
| Purification | Affinity Purified |
| Specificity | Phospho-p16 (ser152) Polyclonal Antibody detects endogenous levels of p16 protein only when phosphorylated at S152. |
| Molecular Weight | Observed: 20 kDa |
| UniProt / Swiss-Prot | P42771 (Human) | P51480 (Mouse) |
Recommended dilutions: WB 1:500-1:2000;IHC 1:100-1:300;ELISA 1:5000;IF 1:50-200
Immunogen / Antigen
The antiserum was produced against synthesized peptide derived from human p16-INK4a around the phosphorylation site of Ser152. AA range:107-156
Reactivity Notes
Confirmed cross-reactivity: Human. Confirm suitability for untested species before use.
Scientific Background
alternative products:Isoform 1 and isoform 4 arise due to the use of two alternative first exons joined to a common exon 2 at the same acceptor site but in different reading frames, resulting in two completely different isoforms,disease:Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53.,disease:Defects in CDKN2A are involved in tumor formation in a wide range of tissues.,disease:Defects in CDKN2A are the cause of cutaneous malignant melanoma 2 (CMM2) [MIM:155601]. Inheritance is autosomal dominant. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a preexisting benign nevus, which occurs most often in the skin but also may involve other sites.,disease:Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719].,disease:Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.,function:Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.,function:Capable of inducing cell cycle arrest in G1 and G2 phases. Acts as a tumor suppressor. Binds to MDM2 and blocks its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits the oncogenic action of MDM2 by blocking MDM2-induced degradation of p53 and enhancing p53-dependent transactivation and apoptosis. Also induces G2 arrest and apoptosis in a p53-independent manner by preventing the activation of cyclin B1/CDC2 complexes. Binds to BCL6 and down-regulates BCL6-induced transcriptional repression. Binds to E2F1 and MYC and blocks their transcriptional activator activity but has no effect on MYC transcriptional repression. Binds to TOP1/TOPOI and stimulates its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation. Interacts with NPM1/B23 and promotes its polyubiquitination and degradation, thus inhibiting rRNA processing. Interacts with UBE2I/UBC9 and enhances sumoylation of a number of its binding partners including MDM2 and E2F1. Binds to HUWE1 and represses its ubiquitin ligase activity. May play a role in controlling cell proliferation and apoptosis during mammary gland development.,online information:Database of CDKN2A germline and somatic variants,online information:P16INK4a entry,polymorphism:Genetic variations in CDKN2A may underlie susceptibility to uveal melanoma [MIM:155720]. Uveal melanoma is the most common type of ocular malignant tumor, consisting of overgrowth of uveal melanocytes and often preceded by a uveal nevus.,similarity:Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.,similarity:Contains 4 ANK repeats.,subunit:Does not interact with cyclins, CDC2, CDK2, CDK4, CDK5 or CDK6. Binds to BCL6, E2F1, HUWE1, MDM2, MYC, NPM1/B23, TOP1/TOPOI and UBE2I/UBC9. Interacts with TBRG1. Interacts with CDKN2AIP and E4F1.,subunit:Heterodimer with CDK4 or CDK6. Isoform 3 does not bind to CDK4.,tissue specificity:Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.
Safety & Handling
This antibody is validated for Western Blot, Immunohistochemistry, Immunofluorescence, ELISA. Recommended dilutions: WB 1:500-1:2000;IHC 1:100-1:300;ELISA 1:5000;IF 1:50-200
Confirmed reactivity: Human. Other species should be validated by the user.
Conjugate: Unconjugated.
Store as follows: -15°C to -25°C/1 year(Do not lower than -25°C)
Customization & Add-ons: Can't find exactly what you need? Contact us for custom formats, conjugations, bulk quantities, or related products.